• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Innoviva Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/21/25 4:15:25 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INVA alert in real time by email
    false 0001080014 0001080014 2025-05-19 2025-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549 

     

     

      

    FORM 8-K

      

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 

     

    Date of Report (Date of earliest event reported): May 19, 2025

     

     

     

    INNOVIVA, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

     

    Delaware 000-30319 94-3265960
    (State or Other Jurisdiction of Incorporation) (Commission  File Number) (I.R.S. Employer Identification Number)

     

    1350 Old Bayshore Highway,
    Suite 400

    Burlingame, California 94010

    (650) 238-9600

    (Addresses, including zip code, and telephone numbers, including area code, of principal executive offices) 

    (Former name or former address, if changed since last report) 

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.01 per share INVA The NASDAQ Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    At the Annual Meeting of Stockholders held on May 19, 2025 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2026, as follows:

     

    Members  Number of
    Shares Voted
    For
       Number of
    Shares Voted
    Against or
    Abstained
       Broker Non-
    Votes
     
    Derek Small   45,871,643.44    2,145,705    6,105,926.56 
    Mark A. DiPaolo, Esq.   43,629,755.44    4,211,235    6,105,926.56 
    Jules Haimovitz   45,749,193.44    2,268,223    6,105,926.56 
    Sarah J. Schlesinger, M.D.   45,829,517.44    2,012,833    6,105,926.56 
    Pavel Raifeld   47,288,131.44    729,058    6,105,926.56 

     

    At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 45,767,649.44 shares for, 2,070,275 shares against, 187,652 shares abstaining, and 6,105,926.56 shares of broker non-votes.

     

    Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote for such ratification was 54,008,510 shares for, 118,408 shares against, 4,585 shares abstaining and 0 broker non-votes.

     

     

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INNOVIVA, INC.
         
    Date: May 21, 2025 By: /s/ Pavel Raifeld
        Pavel Raifeld
        Chief Executive Officer

     

     

     

    Get the next $INVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INVA

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    6/18/2024Overweight
    Cantor Fitzgerald
    7/20/2022$16.00Neutral
    Goldman
    2/23/2022$10.00 → $12.00Underweight
    Morgan Stanley
    2/11/2022$28.00Buy
    EF Hutton
    More analyst ratings